Merger - Fair values of assets acquired and liabilities assumed - (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Assets acquired:
Cash and cash equivalents	$ 98,679	$ 20,323
Prepaid expenses and other current assets	6,561	2,326
Property and equipment, net	2,073	681
Total assets	148,540	24,046
Liabilities assumed:
Accounts payable	3,311	2,400
Accrued expenses and other current liabilities	8,025	4,931
Total liabilities	28,658	$ 7,393
Morphimmune Inc
Merger
Common stock issued to Morphimmune shareholders	72,453
Share-based equity awards allocated to consideration paid	14,708
Transaction costs	792
Consideration paid	87,953
Assets acquired:
Cash and cash equivalents	10,068
Prepaid expenses and other current assets	191
Property and equipment, net	646
In Process Research and Development	80,802
Total assets	91,707
Liabilities assumed:
Accounts payable	1,147
Accrued expenses and other current liabilities	2,607
Total liabilities	3,754
Net assets acquired	$ 87,953